Nantilus
Cancer
Thephosphatidylinositol-3-kinase/proteinkinase(PI3K/PKB)signalingpa- way also known as the survival or anti-apoptotic pathway plays an - portant role in controlling cell growth, proliferation and survival. Whatever the mechanism, the prevalence of PI3K/PKB signaling abnormalities in - man cancers an...
Enregistré dans:
| Auteur principal : | |
|---|---|
| Format : | Livre |
| Langue : | anglais |
| Titre complet : | Cancer / edited by Robert H. Bradbury. |
| Édition : | 1st ed. 2007. |
| Publié : |
Berlin, Heidelberg :
Springer Berlin Heidelberg
, [20..] Cham : Springer Nature |
| Collection : | Topics in medicinal chemistry (Berlin. Internet) ; 1 |
| Accès en ligne : |
Accès Nantes Université
Accès direct soit depuis les campus via le réseau ou le wifi eduroam soit à distance avec un compte @etu.univ-nantes.fr ou @univ-nantes.fr |
| Note sur l'URL : | Accès sur la plateforme de l'éditeur Accès sur la plateforme Istex |
| Condition d'utilisation et de reproduction : | Conditions particulières de réutilisation pour les bénéficiaires des licences nationales : https://www.licencesnationales.fr/springer-nature-ebooks-contrat-licence-ln-2017 |
| Contenu : | Overview. Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer. Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress in the Clinic. Survival Signaling. Progress in the Development of Agents to Control the Cell Cycle. HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit. Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy. Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy. Bcr-Abl Kinase Inhibitors |
| Sujets : | |
| Documents associés : | Autre format:
Cancer Autre format: Cancer Autre format: Cancer Autre format: Cancer |
| Résumé : | Thephosphatidylinositol-3-kinase/proteinkinase(PI3K/PKB)signalingpa- way also known as the survival or anti-apoptotic pathway plays an - portant role in controlling cell growth, proliferation and survival. Whatever the mechanism, the prevalence of PI3K/PKB signaling abnormalities in - man cancers and its potential biological effects (e. g. , competitive growth advantage, evasion from apoptosis and therapy resistance) has suggested the potential use of PI3K/PKB pathway modulators as novel targeted therapeutic agents. Following this strategy, a number of compounds have demonstrated antitumor activity in preclinical and clinical settings by targeting directly or indirectly the different components of this pathway. This work covers - cent salient medicinal chemistry achievements in the identi?cation of these pathway modulators, updating recent reports on this class of potential c- cer drugs [1 4]. To help the reader, each section of this piece of work starts with a brief background to understand the target rationale and then moves on to the lead discovery, drug optimization, and clinical results stages as - propriate. A schematic representation of signaling through this pathway and the pathway components covered herein are shown in Fig. 1. Fig. 1 Schematic representation of signaling through the PI3K/PKB pathway 172 C. Garcia-Echeverria 2 Insulin-likeGrowthFactorI Receptor The Insulin-like Growth Factor-I Receptor (IGF-IR) is a member of the - sulin receptor family of tyrosinekinases. This transmembrane-spanning p- tein is composed of two ?-andtwo ?-subunits linked by disul?de bonds |
|---|---|
| Variantes de titre : | With contributions by numerous experts |
| ISBN : | 978-3-540-33120-9 |
| DOI : | 10.1007/978-3-540-33120-9 |